Nuveen
TBPH icon

Nuveen’s Theravance Biopharma TBPH Stock Holding History

Nuveen’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
133,064
+5,386
+4% +$89.2K ﹤0.01% 2518
2026
Q1 		$2.07M Buy
127,678
+38,690
+43% +$684K ﹤0.01% 2266
2025
Q4 		$1.66M Sell
88,988
-3,226
-3% -$53.5K ﹤0.01% 2366
2025
Q3 		$1.35M Sell
92,214
-28,374
-24% -$359K ﹤0.01% 2478
2025
Q2 		$1.33M Sell
120,588
-254,364
-68% -$2.47M ﹤0.01% 2473
2025
Q1 		$3.35M Sell
374,952
-120,775
-24% -$1.12M ﹤0.01% 2122
2024
Q4 		$4.66M Buy
495,727
+48,635
+11% +$443K ﹤0.01% 2015
2024
Q3 		$3.6M Buy
447,092
+104,377
+30% +$904K ﹤0.01% 2138
2024
Q2 		$2.91M Buy
342,715
+182,897
+114% +$1.65M ﹤0.01% 2201
2024
Q1 		$1.43M Hold
159,818
– – ﹤0.01% 2551
2023
Q4 		$1.8M Sell
159,818
-4,770
-3% -$48K ﹤0.01% 2459
2023
Q3 		$1.42M Buy
164,588
+7,259
+5% +$70.1K ﹤0.01% 2433
2023
Q2 		$1.63M Buy
157,329
+2,819
+2% +$31.1K ﹤0.01% 2441
2023
Q1 		$1.68M Sell
154,510
-97,537
-39% -$1.03M ﹤0.01% 2409
2022
Q4 		$2.83M Buy
252,047
+75,874
+43% +$797K ﹤0.01% 2229
2022
Q3 		$1.79M Sell
176,173
-63,989
-27% -$600K ﹤0.01% 2454
2022
Q2 		$2.18M Buy
240,162
+53,256
+28% +$491K ﹤0.01% 2399
2022
Q1 		$1.81M Buy
186,906
+22,116
+13% +$217K ﹤0.01% 2546
2021
Q4 		$1.65M Sell
164,790
-11,927
-7% -$104K ﹤0.01% 2658
2021
Q3 		$1.26M Sell
176,717
-10,955
-6% -$123K ﹤0.01% 2897
2021
Q2 		$2.73M Sell
187,672
-4,215
-2% -$79.2K ﹤0.01% 2561
2021
Q1 		$3.92M Buy
191,887
+1,727
+0.9% +$32.8K ﹤0.01% 2287
2020
Q4 		$3.38M Sell
190,160
-19,473
-9% -$350K ﹤0.01% 2256
2020
Q3 		$3.1M Sell
209,633
-6,020
-3% -$113K ﹤0.01% 2162
2020
Q2 		$4.53M Sell
215,653
-86,492
-29% -$2.22M ﹤0.01% 1952
2020
Q1 		$6.98M Buy
302,145
+30,194
+11% +$756K ﹤0.01% 1515
2019
Q4 		$7.04M Sell
271,951
-5,840
-2% -$113K ﹤0.01% 1804
2019
Q3 		$5.41M Buy
277,791
+56,699
+26% +$1.15M ﹤0.01% 1912
2019
Q2 		$3.61M Buy
+221,092
New +$4.48M ﹤0.01% 2161

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Nuveen's TBPH Position: Q2 2026 in Review

Nuveen increased its Theravance Biopharma (TBPH) stake by 4.2% in Q2 2026, buying an estimated $89.2K and bringing the position to 133,064 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2518.

Nuveen first reported a position in TBPH in Q2 2019 and has held it in 29 quarters since. The position peaked at $7.04M in Q4 2019. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Nuveen held 133,064 shares of Theravance Biopharma worth $2.26M as of Q2 2026.
  • Nuveen bought 5,386 Theravance Biopharma shares in Q2 2026, an estimated $89.2K.
  • Theravance Biopharma made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2518 holding.
  • Nuveen first reported a position in Theravance Biopharma in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Theravance Biopharma position peaked at $7.04M in Q4 2019.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.